FOLH1 and prostate cancer: The Novartis company (Basel, Switzerland) has an ongoing phase III clinical trial to treat castration-resistant prostate cancer with tumor targeted radiotherapy, by using 177Lu-PSMA (clinical trial identifier: NCT03511664).